Exagen is teaming up with a research lab at the University of Washington’s School of Medicine (UW Medicine) to better understand the workings of the immune system in lupus and rheumatoid arthritis. The collaboration involves the lab of Christian Lood, PhD, an assistant professor in the division…
Provention Bio has dosed the first lupus patient enrolled in the Phase 1b/2 trial testing the safety and pharmaceutical properties of its experimental B-cell-targeted therapy PRV-3279. Results from the first part of the PREVAIL study, done in healthy volunteers, are expected for the first half of 2020.
Changes in gut bacteria, or microbiota, during pregnancy and lactation can shift the immune response towards a more pro-inflammatory state that can bolster autoimmune responses and worsen lupus, a mouse study suggests. Pregnant and lactating mice were found to have increased production of inflammatory mediators and dampening of anti-inflammatory…
Scientists have taken a high-resolution photo of a protein complex, called BRISC-SHMT2, that promotes inflammation and is thought to be at the root of lupus symptoms. This factor may represent a new therapeutic target to tackle the disease, and the new findings may help researchers find therapies that disrupt…
In studying how mycophenolate mofetil treatment affects immune cells and blood markers in people with systemic lupus erythematosus (SLE), researchers uncovered an immune pathway that may explain why is lupus suppressed by this medication. Their findings might…
Tofacitinib tablets, a medicine approved to treat rheumatoid and psoriatic arthritis, may work for lessening signs and symptoms of arthritis and skin rash in people with systemic lupus erythematosus (SLE), a…
GlaxoSmithKline (GSK) is recruiting participants for a Phase 3 clinical trial to evaluate the effectiveness and safety of Benlysta (belimumab) in combination with rituximab for treating patients with active systemic lupus erythematosus (SLE). The study will evaluate if the treatment combo is better at sustaining low disease activity or remission than Benlysta…
Eliminating B-cells using a recent form of immunotherapy that employs genetically modified T-cells is able to treat lupus in mice in a stable and efficient way, a study funded by Lupus Research Alliance shows.
People with lupus nephritis who have nephrotic syndrome — loss of protein in urine, low albumin levels in circulation, elevated lipid levels, and swelling — are less likely to have a kidney response over one year, a review study of two clinical trials shows. It also…
Rituxan (rituximab) is not effective at treating moderate to severe systemic lupus erythematosus (SLE)Â patients without kidney involvement, a new analysis of the Phase 2/3 trial EXPLORER concluded. The results confirm a prior analysis…